Jimenez 4/18/14 "Alcon...consolidate into one business unit"

Google it. He says alcon is underperforming and he will cut $6 billion in cost by consolidating into one internal business unit. No sure what exactly this means but the word "consolidating" does not equal job stability. Writing is on the wall for everyone. Black and white.

 

McKinsey plan is to eliminate all back-office functions: IT, finance, HR/staffing, most of training, legal, benefits administration: this alone will result in 35% reduction of Alcon's G & A expenses year-over-year (with mass layoffs of course). Further cut-backs in physical infrastructure, virtualization of functions, streamlining operations processes will provide another 27% reduction.

Time to leave Alcon and run

 

You guys dont know what novartis business services is? Or where its located.

 

I did Google it and could not find it but I found this:

http://www.thepharmaletter.com/article/novartis-outlines-aims-to-be-more-profitable-and-increasingly-focused

 

Novartis business services was annouced this spring. Nvs will take all sales support, hr, IT etc. From every division.....from every country and move it to india. Its already starting. Not a rumor. The campus is up and running. Nvs has said it will save them $6 billion. And add 2 margin points to the bottom line.

 

Have you been to the campus, its crawling with contractors from India.

 

(1) Not just to India: shared services hubs are being set up in Hyderabad (India), Prague (Czech Republic), as well as Dublin (Ireland) (although the Dublin site is on a smaller scale)

There is also a hub being set up in Latin America (Argentia) for PharmacoVigilance and other functions

(2) The problem is, even with this shared services hub model, we still have the problem of too many Global heads/Heads/Exec & Senior Directors for IT, IGM, GIS, eCompliance, ITQA and what have you, not to mention CIOs & heads of It around every corner costing the company $300K per year, and providing minimal value: if we get rid of these losers, that alone will add to the bottom line

 

This is strange: it costs a fortune to import labor from India, not to mention the violation of immigration and US labor laws: half these smelly losers sneak in using fake certifications, sham diplomas, and unverifiable experience

 

couldn't have said it better.

 

What a joke...I wonder how much Falcon has helped Sandoz. They knew when they bought us that our branded Pharma was weak, but Surgical is kicking ass and they don't know what the hell to do with it.

 

The reality is IOL is in the toilet, as is eye care. With Dailies becoming more popular, the solutions aren't selling. Joe is pissed and Jeff has to do something about it.

 

"big corporate" science is usually behind the curve.
the restructuring is all about increasing free cash flow so that treasury "war chest" is big enough to invest in the future cures for blindness and reversal of vision loss.
such things are produced by real scientists, like Robert Lanza:

http://www.technologyreview.com/news/526591/stem-cell-treatment-for-blindness-moving-through-patient-testing/
Stem-Cell Treatment for Blindness Moving Through Patient Testing
Advanced Cell Technology is testing a stem-cell treatment for blindness that could preserve vision and potentially reverse vision loss.
By Susan Young on April 16, 2014

A new treatment for macular degeneration is close to the next stage of human testing—a noteworthy event not just for the millions of patients it could help, but for its potential to become the first therapy based on embryonic stem cells.

This year, the Boston-area company Advanced Cell Technology plans to move its stem-cell treatment for two forms of vision loss into advanced human trials. The company has already reported that the treatment is safe (see “Eye Study Is a Small but Crucial Advance for Stem-Cell Therapy”), although a full report of the results from the early, safety-focused testing has yet to be published. The planned trials will test whether it is effective. The treatment will be tested both on patients with Stargardt’s disease (an inherited form of progressive vision loss that can affect children) and on those with age-related macular degeneration, the leading cause of vision loss among people 65 and older.

The treatment is based on retinal pigment epithelium (RPE) cells that have been grown from embryonic stem cells. A surgeon injects 150 microliters of RPE cells—roughly the amount of liquid in three raindrops—under a patient’s retina, which is temporarily detached for the procedure. RPE cells support the retina’s photoreceptors, which are the cells that detect incoming light and pass the information on to the brain.

Although complete data from the trials of ACT’s treatments have yet to be published, the company has reported impressive results with one patient, who recovered vision after being deemed legally blind. Now the company plans to publish the data from two clinical trials taking place in the U.S. and the E.U. in a peer-reviewed academic journal. Each of these early-stage trials includes 12 patients affected by either macular degeneration or Stargardt’s disease.

...

Robert Lanza speaking on Biocentrism:
https://www.youtube.com/watch?v=7z61aAmTpIk